Akebia Therapeutics Receives Nasdaq Minimum-Bid-Price Notice

Akebia said its stock closed below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, violating Listing Rule 5550(a)(2). The notice does not immediately affect its listing; the company has until April 19, 2027, to regain compliance.